An RNA nanosensor for the diagnosis of antibiotic resistance in m. Tuberculosis

Active Project Grant Awarded Last action

Award ID
R01AI176498
Recipient
Awarding agency
Obligated
$2,172,351

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 63% complete
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

Description

Abstract
Mycobacterium tuberculosis (MTB) has among the highest resistance rates of any pathogen globally, but MTB resistance remains the most challenging to diagnose due to its very slow growth in in vitro culture and culture's inordinate cost and biohazard. Rapid and accurate alternative diagnostic approaches are urgently needed. DNA based tests are available for detecting resistance to a few drugs but are limited by their need for extensive knowledge of DNA resistance determinants for interpretation, and concerns about limit of detection at the point- of-care. For novel antibiotics entering clinical use, genetic resistance determinants are particularly poorly understood and may be too dispersed across the genome to lend themselves to targeted sequencing and delays in understanding mechanisms may miss an opportunity to avoid more widespread resistance. A work around is the development of a functional or phenotypic assay that circumvents the need to target specific genetic mechanisms, however there is no such rapid assay currently commercially available largely because these assays have traditionally relied on observed bacterial growth in vitro under antibiotic pressure. Leveraging considerable preliminary data from our group and others, we propose the development of an innovative 'functional' RNA-based assay for resistance diagnosis in MTB. We anticipate increasing sensitivity of resistance detection, expanding the numbers of drugs to which resistance can be detected, while significantly shortening time-to-result. Specifically, in this early phase development proposal we will identify key assay parameters that maximize the MTB RNA susceptibility signal to five key agents in multi-drug resistant tuberculosis treatment (bedaquiline, pretomanid, linezolid, moxifloxacin and pyrazinamide) using RNA sequencing in a factorial design of experiments assessing drug exposure dose and exposure duration. In addition, we will study the effect of key clinical variables including genetic resistance mechanism, background lineage (aim 1). In aim 2 we will work with nanostring technologies to develop hybridization probe sets (that we call nanosensors for short) to target antibiotic responsive and control genes in two iterative phases. This will be followed by assay performance assessment in vitro, and on sputum from participants newly diagnosed with rifampicin resistant TB before and after incubation in culture media. This work will build a strong foundation for an innovative resistance diagnostic that addresses an unmet need.

Transactions

Action Obligated Date
Amendment $269,163
Amendment $427,444
Amendment $705,150
Original award $770,594

Subawards

Subrecipient Amount Awarded
South African Medical Research Council The South African Medical Research Council (SAMRC) will serve as our implementing partner. The SAMRC will serve as a subgrantee in support of the proposed… $93,167
Stellenbosch University Dr. Warren from Stellenbosch University will ensure the training of Dr. Brendon Mann (Junior Scientist), Dr. Grobbelaar, research assistant and chief laboratory… $446,790
Boston Medical Center Corporation Dr. Karen Jacobson will be the subcontract PI for Boston Medical Center and Co-Investigator on this proposal, in part overseeing conduct of activities at BMC,… $153,811
Stellenbosch University Dr. Warren from Stellenbosch University will ensure the training of Dr. Brendon Mann (Junior Scientist), Dr. Grobbelaar, research assistant and chief laboratory… $0
Stellenbosch University $214,067
Boston Medical Center Corporation Dr. Karen Jacobson will be the subcontract PI for Boston Medical Center and Co-Investigator on this proposal, in part overseeing conduct of activities at BMC,… $302,305

Quick answers

Who received award R01AI176498?

R01AI176498 was awarded to President And Fellows Of Harvard College by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 13, 2023.

How much is award R01AI176498 worth?

$2,172,351 has been obligated on R01AI176498.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award